Companies in #Epilepsy

Genetics-driven precision medicine company developing small molecule therapeutics for rare and common diseases. Pipeline includes KCNT1 inhibitor for epilepsy and TRPV4 inhibitor for Charcot-Marie-Tooth disease. Acquired by Jazz Pharmaceuticals for $820M.

Artelo Biosciences is a clinical-stage biopharmaceutical company developing therapeutics that modulate lipid-signalling pathways, including the endocannabinoid system. Its pipeline is led by ART27.13, a synthetic peripherally selective dual cannabinoid G protein-coupled receptor agonist in Phase 1b/2a for cancer-related anorexia, which in September 2026 reported nonclinical data in a diet-induced obesity model showing weight loss comparable to semaglutide as a monotherapy and roughly double that of semaglutide alone in combination. ART26.12 is a fatty acid binding protein 5 (FABP5) inhibitor in development for chemotherapy-induced peripheral neuropathy, diabetic neuropathy, prostate and breast cancer, and pain, while ART12.11 is a cocrystal composition of cannabidiol and tetramethylpyrazine being evaluated for anxiety, depression, post-traumatic stress disorder, epilepsy and insomnia. The company was incorporated in 2011 as Reactive Medical Inc. and renamed Artelo Biosciences in April 2017.

Clinical-stage biotechnology company developing precision genetic medicines for severe neurological disorders, with lead gene therapy ETX101 for Dravet syndrome.

Filana Therapeutics is a clinical-stage biopharmaceutical company developing simufilam, a small-molecule modulator of filamin A, for tuberous sclerosis complex (TSC)-related epilepsy. Formerly known as Cassava Sciences and, before that, Pain Therapeutics, the company rebranded and refocused on refractory TSC-associated seizures in March 2026 after an earlier Alzheimer's disease development programme. In September 2026 the FDA lifted a full clinical hold on the company's investigational new drug application for simufilam, clearing the way for a planned 16-week, multicenter, randomized, double-blind Phase 2a proof-of-concept study evaluating two doses in 40 patients aged 12 to 55 at 13 U.S. sites, with patient screening expected to begin in the first quarter of 2027.

Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into precision therapies for central nervous system (CNS) disorders, with a focus on epilepsy and broader neuroscience.

Global CNS-focused biopharmaceutical company developing and commercialising treatments for epilepsy, sleep disorders and oncology, including cenobamate (XCOPRI/Ontozry).

Public biopharma (Nasdaq: SUPN) developing and commercializing CNS therapeutics across epilepsy, migraine, Parkinson's disease, ADHD and postpartum depression; agreed to an all-stock merger with Indivior in 2026.

Services: Belgium-based global biopharmaceutical company specializing in central nervous system (CNS) and immunology diseases. Marketed products include Cimzia (immunology), Keppra, Vimpat, Briviact (epilepsy), and Rystiggo (myasthenia gravis). Active R&D pipeline in neurology, immunology, and rare diseases. Leadership: CEO (Cyril) - headquartered in Brussels, Belgium. EVP/Head of Neurology Charl van Zyl (departed for Lundbeck CEO role 2023). Keywords: Belgian biopharma, CNS, immunology, epilepsy, myasthenia gravis, Cimzia, Briviact

Neurology-focused biopharmaceutical company applying its Extreme Genetics discovery platform to Kv7 and other ion-channel modulators, led by azetukalner for epilepsy and major depressive disorder.